Cisplatin resistance of TMEM16A overexpressing head and neck tumors and cancer models is driven by increased lysosomal flux and reversed by Hydroxychloroquine. (October 2022) - Vyas, A.; Cruz-Rangel, S.; Pacheco, J.; Hammond, G.; Kiselyov, K.; Duvvuri, U.